The use of prostate-specific antigen (PSA) to screen for prostate cancer remains controversial. Although it is still too early to measure directly the effects of PSA screening on mortality, we examined changes in the epidemiology of prostate cancer to determine if there is other evidence of the effectiveness of PSA as a screening tool.
Division of Urology, Robert Wood Johnson Medical School, The Environmental and Occupational Health Sciences Institute, New Brunswick, New Jersey 08903-0019, USA.
